Category: Cardiac Rhythm ManagementSyndicate content

St. Jude cries victory with its quadripolar leads

September 4, 2014 by Arezu Sarvestani

St. Jude Medical says that its Quartet quadripolar leads "performed better than bipolar leads of any kind" in a recent mega-study.

St. Jude cries victory with its quadripolar leads

Medical device giant St. Jude Medical (NYSE:STJ) had high praise for its own quadripolar leads, saying that blow away any competition from older bipolar leads.

Pacemakers learn from wristwatches to ditch batteries

September 3, 2014 by Arezu Sarvestani

Another team of researchers is working on pacemakers that use motion for power, with aims to eliminate reliance on depletable batteries.

Pacemakers learn from wristwatches to ditch batteries

Swiss researchers are taking a page from their country's most iconic products to change how pacemakers are powered inside the body.

CorMatrix lands FDA win, touts 1st human implant of CanGaroo surgical pouch

August 28, 2014 by Arezu Sarvestani

CorMatrix secure FDA clearance for its CanGaroo ECM envelope for use with implantable cardiac devices and touts 1st human use in a patient at Ohio's Cleveland Clinic.

CorMatrix lands FDA win, touts 1st human implant of CanGaroo surgical evelope

Georgia medical device maker CorMatrix touted an FDA win this month, landing regulatory clearance for its CanGaroo surgical envelope for securing implantable cardiac devices.

Press Release: CorMatrix reports FDA clearance of CorMatrix CanGaroo ECM Envelope

August 28, 2014 by MassDevice

Press Release: CorMatrix reports FDA clearance of CorMatrix CanGaroo ECM Envelope

Roswell, Georgia – CorMatrix Cardiovascular announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market the CorMatrix CanGaroo ECM Envelope for use with cardiac implantable electronic devices (CIED's) including pacemakers and implantable cardioverter defibrillators (ICD's).

Medtronic launches personalized heart rhythm therapy trial

August 27, 2014 by Arezu Sarvestani

Medtech titan Medtronic enrolls the 1st patients in the AdaptResponse clinical trial to evaluate its adaptive cardiac rhythm management technology.

Medtronic launches personalized heart rhythm therapy trial

Medtronic (NYSE:MDT) touted the launch of its AdaptResponse trial, the largest study of its kind evaluating the company's AdaptivCRT algorithm for personalizing cardiac resynchronization therapy in treatment of heart failure.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Judge agrees to toss ex-Biosense rep's suit in non-compete row with St. Jude Medical

August 27, 2014 by Brad Perriello

A federal judge agrees to toss a lawsuit filed against Johnson & Johnson's Biosense Webster by a former sales rep and her new employer, St. Jude Medical.

Judge agrees to toss ex-Biosense rep's suit in non-compete row with St. Jude Medical

Medtronic's personalized pacemaker wins FDA approval

August 25, 2014 by Arezu Sarvestani

FDA regulators approve Medtronic's new Viva CRT-P adaptive cardiac pacemaker for treatment of heart failure or atrioventricular block.

Medtronic's personalized pacemaker wins FDA approval

Medtronic (NYSE:MDT) won FDA approval for its Viva CRT-P cardiac resynchronization therapy-pacemaker, which features proprietary software to adjust its pacing parameters to a patient's heart rhythms minute-by-minute.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp